Redeye: Coegin Pharma Q3 - Further business developments
Redeye provides a research update following the Q3 report recently published by Coegin Pharma. While the report itself did not include any significant surprises, the company manages to continue operating on a low cash burn. However, the quarter was primarily marked by the company’s TO3 warrants period. As the company has successfully raised some much-needed capital, we see enticing potential in the stock.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/